SW
ALNY icon

SteelPeak Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

SteelPeak Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,484
Closed -$590K – 578
2025
Q4 		$590K Sell
1,484
-151
-9% -$66.8K 0.02% 333
2025
Q3 		$745K Sell
1,635
-1,173
-42% -$478K 0.02% 339
2025
Q2 		$916K Buy
2,808
+81
+3% +$22.4K 0.04% 274
2025
Q1 		$736K Sell
2,727
-753
-22% -$194K 0.03% 297
2024
Q4 		$819K Buy
3,480
+1,005
+41% +$264K 0.03% 276
2024
Q3 		$681K Sell
2,475
-1,071
-30% -$279K 0.03% 271
2024
Q2 		$862K Sell
3,546
-3,314
-48% -$523K 0.04% 244
2024
Q1 		$1.03M Buy
6,860
+4,090
+148% +$682K 0.05% 214
2023
Q4 		$530K Sell
2,770
-1,655
-37% -$282K 0.03% 272
2023
Q3 		$784K Buy
4,425
+1,408
+47% +$269K 0.05% 206
2023
Q2 		$573K Buy
3,017
+322
+12% +$63.8K 0.03% 231
2023
Q1 		$540K Buy
2,695
+276
+11% +$58K 0.04% 231
2022
Q4 		$575K Sell
2,419
-1,047
-30% -$223K 0.04% 225
2022
Q3 		$694K Buy
3,466
+9
+0.3% +$1.72K 0.05% 199
2022
Q2 		$504K Buy
+3,457
New +$490K 0.04% 250

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SteelPeak Wealth's ALNY Position: Q1 2026 in Review

SteelPeak Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,484 shares — an estimated $590K sold.

SteelPeak Wealth first reported a position in ALNY in Q2 2022 and held it in 15 quarters. The position peaked at $1.03M in Q1 2024. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • SteelPeak Wealth reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SteelPeak Wealth sold 1,484 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $590K.
  • SteelPeak Wealth first reported a position in Alnylam Pharmaceuticals in Q2 2022 and held it in 15 quarters.
  • SteelPeak Wealth's Alnylam Pharmaceuticals position peaked at $1.03M in Q1 2024.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on SteelPeak Wealth's 13F filing for Q1 2026, filed 5 May 2026.